Related Experiment Videos

Childhood anemia in Africa: to transfuse or not transfuse?

B R Holzer1, M Egger, T Teuscher

  • 1St. Francis Designated District Hospital, Ifakara, Kilombero, Tanzania.

Acta Tropica
|October 1, 1993
PubMed

Insights

Blood transfusions for childhood anemia in high HIV prevalence areas showed similar packed cell volume (PCV) levels compared to no transfusion. Further research is needed to weigh the risks and benefits of transfusions in these regions.

Area of Science:

  • Public Health
  • Infectious Diseases
  • Pediatrics

Background:

  • Blood transfusions are a significant transmission route for Human Immunodeficiency Virus (HIV) in Africa.
  • Childhood anemia is prevalent in holoendemic malaria regions, often managed with blood transfusions.

Purpose of the Study:

  • To evaluate the necessity and impact of blood transfusions in managing childhood anemia in a high HIV prevalence setting.
  • To compare packed cell volume (PCV) levels and clinical outcomes in anemic children receiving transfusions versus those treated with medication alone.

Main Methods:

  • A randomized trial involving 116 children with anemia in Ifakara, Tanzania.
  • Participants were assigned to receive either malaria and hookworm treatment alone or with the addition of HIV-screened whole blood transfusion.
  • Packed cell volume (PCV) was measured at admission, 2 days, 4 weeks, and 8 weeks post-entry.

Main Results:

  • Mean PCV at admission was comparable between the transfusion (14.0%) and no transfusion (14.4%) groups.
  • After 8 weeks, PCV levels were similar in both groups (22.9% vs. 23.6%).
  • A trend towards increased hospital admissions and deaths was observed in the no transfusion group, though confidence intervals were wide.

Conclusions:

  • Blood transfusions did not significantly improve PCV levels in anemic children compared to standard treatment in this study.
  • The potential benefits and risks of blood transfusions, particularly concerning HIV transmission, require careful consideration in policy-making.
  • A larger randomized trial is essential to definitively assess the cost-benefit ratio and safety of blood transfusions for childhood anemia in high HIV prevalence areas.

Related Concept Videos